Encorafenib and QTc prolongation
Result of checking the interaction of drug Encorafenib and disease QTc prolongation for safety when used together.
When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.
Consumer:Encorafenib is associated with dose-dependent QTc interval prolongation in some patients. Monitor patients who already have or who are at significant risk of developing QTc prolongation, including patients with known long QT syndromes, clinically significant bradyarrhythmias, severe or uncontrolled heart failure and those taking other medicinal products associated with QT prolongation. Correct hypokalemia and hypomagnesemia prior to and during therapy with encorafenib. Withhold, reduce dose, or permanently discontinue for QTc > 500 ms.
Encorafenib - Wydłużenie QTc 
Encorafenib - Prolongamento QTc 
Encorafenib - Pemanjangan QTc 
Encorafenib - Perpanjangan QTc 
Encorafenib - Prolungamento dell'intervallo QTc 
Encorafenib - Allongement de l'intervalle QTc 
Encorafenib - QTc-Verlängerung 
Encorafenib - Prolongación de QTc 
Encorafenib - удлинение QTc 
Encorafenib - QTc uzaması 
Encorafenib - إطالة كيو تي سي 
Encorafenib - QTc延长